Zydus Lifesciences, a prominent player in the global healthcare sector, has unveiled Rexigo, the first-ever oral once-a-day therapy designed for testosterone suppression in patients with advanced prostate cancer in India.

Prostate cancer, a leading cause of concern among men, witnessed more than 43,000 reported cases in India in 2022, as per the National Cancer Registry Program. With the introduction of Rexigo, Zydus Lifesciences aims to revolutionize the treatment landscape by offering a groundbreaking, cost-effective alternative.

Key Features of Rexigo:

1. Affordability: Priced at Rs 6,995 per month, Rexigo stands as a cost-effective solution, providing patients with a 50% reduction in treatment expenses compared to existing injectable options.
2. Innovative Oral Therapy: Rexigo introduces a paradigm shift in prostate cancer management by eliminating the need for injectables, offering patients a convenient and hassle-free oral treatment option.
3. Rapid Action and Safety: Featuring the globally recognized active component Relugolix, Rexigo ensures swift testosterone suppression and boasts a superior safety profile for heart-related adverse events.
4. Market Impact: Zydus Lifesciences Ltd.’s shares witnessed a 1.19% surge post the Rexigo launch, underscoring the positive market response and anticipation of the drug’s transformative impact on advanced prostate cancer treatment.

Zydus Lifesciences has been a trailblazer in the Oncology segment, consistently prioritizing patient needs. The launch of Rexigo underscores the company’s commitment to enhancing accessibility and affordability in cancer therapies.

“We are proud to introduce Rexigo, a game-changer in the field of advanced prostate cancer treatment. With its innovative oral formulation, affordability, and rapid action, Rexigo is poised to redefine the standards of care in prostate cancer management,” stated a spokesperson from Zydus Lifesciences.

Also Read | Aveya Fertility Launches First-Ever Cervical Cancer Vaccination Drive in Collaboration with Infinite Fertility

The launch of Rexigo marks a historic moment in the fight against advanced prostate cancer in India. Zydus Lifesciences, known for its commitment to patient-centric solutions, continues to lead the way in bringing transformative therapies to the market. Rexigo’s innovative approach and cost-effectiveness set a new standard for advanced prostate cancer treatment.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.